Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines.
BACKGROUND
It is more and more recognized that hypoxia plays a role in the resistance of cancer cells to chemotherapy. However, the mechanisms underlying this resistance still need deeper understanding. The aim of this study was to investigate the effect of hypoxia on this process since hypoxia is one of the hallmarks of tumor environment.


RESULTS
The effect of hypoxia on the apoptosis induced by etoposide, one drug commonly used in chemotherapy, was investigated using three different cancer cell lines. Gene expression changes were also studied in order to delineate the mechanisms responsible for the hypoxia-induced chemoresistance. We observed that hypoxia differentially influenced etoposide-induced cell death according to the cancer cell type. While hypoxia inhibited apoptosis in hepatoma HepG2 cells, it had no influence in lung carcinoma A549 cells and further enhanced it in breast cancer MCF-7 cells. Etoposide increased p53 activity in all cell lines while hypoxia alone decreased it only in HepG2 cells. Hypoxia had no influence on the etoposide-induced p53 activity in A549, increased p53 abundance in MCF-7 cells but markedly decreased p53 activity in HepG2 cells. Using low density DNA arrays to detect the expression of genes involved in the regulation of apoptosis, etoposide and hypoxia were shown to each influence the expression of numerous genes, many of the ones influenced by etoposide being p53 target genes. Again, the influence of hypoxia on the etoposide-induced changes was different according to the cell type.


CONCLUSIONS
These results evidenced that there was a striking parallelism between the effect of hypoxia on the etoposide-induced p53 stabilization as well as p53 target gene expression and its effect on the etoposide-induced apoptosis according to the cell type. They are very interesting not only because they provide one possible mechanism for the induction of chemoresistance under hypoxic conditions in cells like HepG2 but also because they indicate that not all cell types respond the same way. This knowledge is of importance in designing adequate treatment according to the type of tumors.
Cosse
Jean-Philippe
JP
Laboratory of Biochemistry and Cellular Biology (URBC), FUNDP-University of Namur, 61 rue de Bruxelles, 5000 Namur, Belgium. jean-philippe.cosse@fundp.ac.be
Sermeus
Audrey
A
Vannuvel
Kayleen
K
Ninane
Noelle
N
Raes
Martine
M
Michiels
Carine
C
D017209:Apoptosis / Q000187:drug effects*; D015687:Cell Hypoxia / Q000502:physiology; D045744:Cell Line, Tumor; D004247:DNA / Q000235:genetics; D004249:DNA Damage / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D020411:Oligonucleotide Array Sequence Analysis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D051793:Hypoxia-Inducible Factor 1; D016159:Tumor Suppressor Protein p53; D005047:Etoposide; D004247:DNA